Nathan Wong/LinkedIn
Feb 1, 2026, 11:24
Nathan Wong on Economic Benefits of Inclisiran for LDL-C Control
Nathan Wong, Professor and Director, Heart Disease Prevention Program, Division of Cardiology, UC Irvine, shared on LinkedIn:
”Our latest paper in JACC Journals projects approximately 20 million US adults with inadequately controlled LDL-C on statins could benefit from inclisiran treatment, preventing more than 1.6 million ASCVD events over 10 years.”
Read the full article here.
Article: Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
Authors: Nathan Wong, Hridhay Karthikeyan, Wenjun Fan, Batul Electricwala
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 26, 2026, 13:58Peter Bou Dib: How Factor IX Transformed Hemophilia B Treatment
-
Jun 26, 2026, 13:49Raghavendra Rao: The Surprising Link Between Chronic Venous Insufficiency and Falls
-
Jun 26, 2026, 13:40Caylynn Carls: Why Genetic Counseling Matters in Hemophilia Treatment
-
Jun 26, 2026, 13:25Ángel Cabrera: Clotting Disorders Behind Heavy Menstrual Bleeding
-
Jun 26, 2026, 13:02Turid Kjellevold: The Critical Role of Timely Hemostasis Testing
-
Jun 26, 2026, 10:59Wolfgang Miesbach: How Clonal Hematopoiesis May Explain Age-Related Mitochondrial Mutations
-
Jun 26, 2026, 10:52Chinua Onyebuchi: The Future of Stroke Care in Africa Lies in Strong Health Systems
-
Jun 26, 2026, 10:35Habtamu Milkias Wolde: New Insights into Stroke and Traumatic Brain Injury from Global Burden of Disease Data
-
Jun 26, 2026, 10:19Rytis Masiliūnas: Atrial Fibrillation and Stroke Care Disparities Across the Baltic Region